Abstract
Even today, heart failure due to doxorubicin‐induced dilated cardiomyopathy seems to have a poor prognosis, as it is often irreversible and relatively unresponsive to standard medical treatment. This paper describes the first case of a patient complaining of severe symptoms of congestive heart failure due to doxorubicin‐induced dilated cardiomyopathy unresponsive to standard medical treatment (digoxin, diuretics, and angiotensin‐converting enzyme inhibitor), who showed complete clinical recovery and significant improvement of left ventricular dysfunction after carvedilol treatment. It also illustrates the possibility that carvedilol may be a first‐choice drug for the treatment of this disease.
Keywords: doxorubicin, cardiomyopathy, carvedilol
Full Text
The Full Text of this article is available as a PDF (513.1 KB).
References
- 1. Young RC, Ozol RF, Myers CE: The anthracycline antineoplastic drugs. N Engl J Med 1981; 305: 139–153 [DOI] [PubMed] [Google Scholar]
- 2. van Hoff DD, Layard MW, Basa P, Davis HL Jr, von Hoff AL, Rozencweig M, Muggia FM: Risk factors for doxorubicin‐induced congestive heart failure. Ann Intern Med 1979; 91: 710–717 [DOI] [PubMed] [Google Scholar]
- 3. Choen M, Kronzon I, Lebowitz A: Reversible doxorubicin‐induced congestive heart failure. Arch Intern Med 1982; 142: 1570–1571 [PubMed] [Google Scholar]
- 4. Saini J, Rich MW, Lyss AP: Reversibility of severe left ventricular dysfunction due to doxorubicin cardiotoxicity. Report of three cases. Ann Intern Med 1987; 106: 814–816 [DOI] [PubMed] [Google Scholar]
- 5. Gianni L, Corden BJ, Myers CE: The biochemical of anthracycline toxicity and anti tumoral activity In Reviews in Biochemical Toxicology (Eds. Hodgson E, Philport RM.), p. 1–82. Amsterdam: Elsevier, 1983. [Google Scholar]
- 6. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983; 43: 460–472 [PubMed] [Google Scholar]
- 7. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349–1355 [DOI] [PubMed] [Google Scholar]
- 8. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein G: Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92–98 [PubMed] [Google Scholar]
- 9. Bril A, Slivjak M, Di Martino MJ, Feuerstein GZ, Linee P, Poyser RH, Ruffolo RR Jr, Smith EF : Cardioprotective effects of carvedilol, a novel beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs: Comparison with propranolol. Cardiovasc Res 1992; 26: 518–525 [DOI] [PubMed] [Google Scholar]